 Fate Therapeutics Inc NASDAQ: FATE revealed an early cut of Phase I data for its FT596 and FT516 programs for relapsed refractory B-cell lymphoma. At the 2021 American Society of Clinical Oncology Meeting, the Company highlighted positive interim FT516 program data for 11 pretreated patients. 